Skin & hair

The Light Treatments That Coax Color Back

Save

Vitiligo happens when the immune system destroys the pigment cells in patches of skin, and light therapy is one of the few treatments with real evidence behind it. This piece walks through how narrowband UVB and excimer laser compare, who tends to respond best, and how they fit alongside newer options like topical ruxolitinib.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Does Narrowband UVB Actually Regrow Pigment?

Yes — narrowband UVB phototherapy is the light treatment with the strongest evidence behind it for vitiligo, and a systematic review pooling multiple trials found it produces meaningful repigmentation in a substantial share of patients, with the response building over months of consistent treatment rather than appearing after a handful of sessions 1. Narrowband UVB is the best-evidenced light treatment for vitiligo, but it works by slow accumulation, not a quick fix. It's administered as regular sessions — commonly a few times a week — in a specialized light box or booth that exposes the skin to a narrow, targeted band of ultraviolet light shown to stimulate the pigment-producing cells that vitiligo destroys.

Why Vitiligo Patches Form in the First Place

Vitiligo is a chronic autoimmune condition in which the immune system attacks and destroys melanocytes, the cells that produce pigment, leaving behind smooth, milky-white patches of skin that can appear anywhere on the body and at any age 2. There's no cure, but the same source is clear that treatment can stabilize the patches and, in many cases, bring some color back — light therapy is one of the main tools for that second goal, not the first. Understanding vitiligo as autoimmune rather than cosmetic explains why treatment takes months: it's coaxing surviving or migrating pigment cells back to work, not applying a stain.

How an Excimer Laser Differs From a Full-Body Light Box

An excimer laser delivers the identical narrow wavelength of UVB light used in a light box, but through a handheld device aimed only at the patches that need it, rather than the whole body at once. That precision makes it a common choice for smaller, well-defined patches — on the face, hands, or genitals — where treating unaffected skin would mean unnecessary UV exposure for no benefit. Full-body narrowband UVB, by contrast, makes more sense when vitiligo is spread across many areas, since covering each patch individually with a handheld device becomes impractical. What happens inside a course of narrowband UVB — how many sessions, how visits are spaced, what a booth session actually involves — is worth walking through on its own; here, the more useful question is which format, booth or excimer, fits a given case.

Who Tends to Do Better With Which Format

The choice between excimer laser and full-body narrowband UVB mostly comes down to how much skin is involved and where. Excimer suits a handful of stable patches; whole-body narrowband UVB suits vitiligo scattered across many sites. Acral vitiligo, the term for patches on the hands and feet, is worth naming here because it behaves differently: these are widely recognized among the places vitiligo resists the most, responding more slowly and less completely to either format than patches on the face, neck, or trunk. That doesn't rule light therapy out for acral disease, but it does mean expectations are usually set lower going in, and a clinician may combine formats or add another treatment specifically for those areas. Access also factors in practically: a full-body booth is typically found only at a dermatology office or specialized clinic, while some people use a smaller excimer device or a supervised home unit for a handful of stable patches, which can mean fewer trips overall for limited disease.

How Long Before You'd See a Change

Repigmentation from either format is a matter of months, not weeks — the meta-analysis behind narrowband UVB's evidence found that response continued to build the longer treatment continued, meaning early sessions that show little change aren't necessarily a sign the treatment has failed 1. Clinicians typically ask for a defined trial period before judging whether a given course is working, since stopping too early is one of the most common reasons phototherapy gets written off as ineffective. A typical course involves sessions several times a week for months, which is a real logistical commitment worth planning around — clearing a spot in a weekly schedule for months, not weeks, before assessing whether it's working. Slow, patchy early progress is expected and does not mean the treatment isn't working — most repigmentation with phototherapy builds over months.

When Does Light Therapy Become the Next Step?

Light therapy usually enters the conversation after a topical treatment — a corticosteroid or calcineurin-inhibitor cream — has been given a fair trial and repigmentation is minimal, or when vitiligo covers enough of the body that treating it patch by patch with a cream alone isn't practical. It's also considered directly, without waiting on a topical trial, when patches are spreading quickly, since earlier treatment generally has more pigment-producing cells left to work with. This is a decision made with a dermatologist looking at the specific pattern and pace of a person's vitiligo, not a fixed timeline that applies to everyone — some clinicians move to phototherapy within a couple of months of an unsuccessful topical trial, others wait longer depending on how the case is progressing.

Where Light Therapy Fits Next to Newer Topical Options

Light therapy isn't the only tool with trial evidence behind it anymore. Topical ruxolitinib, a JAK-inhibitor cream, was shown in two phase 3 trials to produce significantly more facial and total-body repigmentation than an inactive cream in people 12 and older with nonsegmental vitiligo 3, giving clinicians a second evidence-backed option to reach for alongside or instead of light. In practice, the two are often paired rather than chosen between: combining phototherapy and cream for vitiligo is a common strategy, on the reasoning that a topical medication calming the immune attack and a light source stimulating pigment cells work on different parts of the same problem. A fuller look at the vitiligo treatment options and how they stack up against each other, including where ruxolitinib fits relative to phototherapy, is useful reading before deciding which combination makes sense for a given case.

Common questions

Neither is universally better — it depends on how much skin is affected. Excimer laser targets a handful of stable patches with precision and can mean fewer total sessions for limited disease. Full-body narrowband UVB makes more sense when vitiligo is spread across several areas, since treating each patch individually with a handheld device becomes impractical. A dermatologist typically weighs the pattern of a person's vitiligo before recommending one.

There's no fixed number — response builds gradually over months of consistent treatment rather than appearing after a handful of visits. Many clinicians ask for a defined trial period, often measured in months, before judging whether a course is working. Stopping early, before that window has passed, is one of the most common reasons phototherapy looks less effective than it actually is.

Sometimes, but not always, and results vary a great deal by where the vitiligo is. Patches on the face, neck, or trunk tend to respond more fully than those on the hands and feet, which are known to resist repigmentation more than other areas. A dermatologist can give a more realistic, individualized sense of what to expect given where the patches are.

Combining a topical medication with light therapy is a common strategy, since they work through different mechanisms — one calms the immune activity attacking pigment cells, the other stimulates those cells directly. Whether combining is right for a given case, and in what sequence, is a decision for a dermatologist familiar with the person's full treatment history, not something to start without guidance.

No — it's a chronic autoimmune condition in which the immune system destroys the cells that produce pigment, not a stain or discoloration. There's currently no cure, but treatments including light therapy and topical medications can stabilize the patches and, for many people, bring back meaningful color over time. Framing it as autoimmune rather than cosmetic also explains why treatment takes months rather than days.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to check in with a dermatologist during light therapy

  • —Blistering, peeling, or significant pain after a phototherapy session, rather than mild pinkness
  • —Rapidly spreading new patches over a matter of weeks, especially alongside fatigue, weight change, or other symptoms that could point to a separate autoimmune condition
  • —Eye pain, light sensitivity, or vision changes after a session, which can signal inadequate eye protection during treatment

This article is general health information, not medical advice. It describes how light therapy for vitiligo generally works but cannot assess an individual case. A dermatologist can determine which format, schedule, and combination of treatments fits a specific pattern of vitiligo.

References

  1. 1.Bae JM, Jung HM, Hong BY, et al. (2017). Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatology. link ✓Narrowband UVB phototherapy produces meaningful repigmentation in vitiligo, with response building over months of consistent treatment.
  2. 2.National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024). Vitiligo. NIH / NIAMS. link ✓Vitiligo is a chronic autoimmune disorder in which melanocytes are destroyed, causing depigmented patches; there is no cure but treatment can stabilize and repigment skin.
  3. 3.Rosmarin D, Passeron T, Pandya AG, et al. (2022). Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine. doi:10.1056/NEJMoa2118828 ✓Topical ruxolitinib cream produced significantly greater facial and total-body repigmentation than vehicle in nonsegmental vitiligo in patients 12 and older.

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library